Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Wei Wang, MD, PhD
Nuvation Bio Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
77 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Mcgill University Health Centre Research Institute
Montreal, Quebec, Canada
- Beijing Cancer Hospital
Beijing, Beijing Municipality, China
- the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
- Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
- Hunan Cancer Hospital
Changsha, China
- West China Hospital
Chengdu, China
- Shandong Cancer Hospital
Jinan, China
- Wuhan Union Hospital
Wuhan, China
- Henan Cancer Hospital
Zhengzhou, China
- Chu Lyon - Hôpital Cardio-Vasculaire Et Pneumologique Louis Pradel
Bron, France
- Chu Grenoble Alpes- Hospital Michallon
La Tronche, France
- Centre Léon Bérard
Lyon 08, France
- Centre D'Essais Précoces de Cancerologie de Marseille
Marseille, France
- Aphp- Hôpital Europeen Georges Pompidou (hegp)
Paris, France
- Chu de Poitiers Pole Regional
Poitiers, France
- Institut Jean Godinot
Reims, France
- Chu Rennes - Hospital Pontchaillou
Rennes, France
- Institut de Cancérologie de L'Ouest
Saint-Herblain, France
- Institut Gustave Roussy
Saint-Herblain, France
- Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico
Bari, Italy
- Humanitas Istituto Clinico Catanese, Misterbinanoco
Catania, Italy
- Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
- Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
- Ieo Istituto Europeo Di Oncologia
Milan, Italy
- Ospedale San Raffaele
Milan, Italy
- Aou Cagliari- P.O. Policlinico Universitario Duilio Casula
Monserrato, Italy
- Azienda Ospedaliera Universitaria- Università Degli Studi Della Campania
Naples, Italy
- Fondazione Policlinico Universitario Agostino Gemelli Irccs
Roma, Italy
- National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
- National Cancer Center Hospital East
Kashiwa, Japan
- Sendai Kousei Hospital
Miyagi, Japan
- Aichi Cancer Center Hospital
Nagoya, Japan
- Kindai University Hospital
Osaka, Japan
- Shizuoka Cancer Center
Shizuoka, Japan
- National Cancer Center Hospital
Tokyo, Japan
- the Cancer Institute Hospital of Jfcr
Tokyo, Japan
- Instytut Centrum Zdrowia Matki Polki
Lodz, Poland
- Med-Polonia Sp. Z O.O.
Poznan, Poland
- Mics Centrum Medyczne Toruńa
Torun, Poland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Sept 2021
- Primary completion
- 11 Jun 2025
- Completion
- 31 Dec 2027
- Last update posted
- 7 Jan 2026
- Registered enrollment
- 217
- Registry id
- NCT04919811
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.